Post-transplantation diabetes mellitus: an overview
https://doi.org/10.14341/DM2015220-31
Abstract
This review presents an analysis of clinical and experimental studies related to post-transplantation diabetes mellitus (PTDM) ? a specific complication after solid organ transplantation.
A search of the databases eLibrary, PubMed and Scopus using the keywords ?posttransplantation diabetes mellitus?, ?new onset diabetes after transplantation?, ?transplantation? and ?immunosuppression? yielded in 523 results, including four from Russian literature (one original research manuscript). The analysis included original research, reviews, meta-analyses and monographs published not before 2005 in Russian and English. A total of 60 relevant original researches and reviews were included in this review.
Diagnostic criteria, disease risk factors and potential pathogenic mechanisms were all considered. The mechanisms of the diabetogenic effect of modern immunosuppressive drugs were analysed. The principles of pre- and post-transplantation screening for PTDM and optimal management strategies for patients with PTDM are presented. The current controversial issues concerning the various aspects of PTDM are discussed.
A search of the databases eLibrary, PubMed and Scopus using the keywords ?posttransplantation diabetes mellitus?, ?new onset diabetes after transplantation?, ?transplantation? and ?immunosuppression? yielded in 523 results, including four from Russian literature (one original research manuscript). The analysis included original research, reviews, meta-analyses and monographs published not before 2005 in Russian and English. A total of 60 relevant original researches and reviews were included in this review.
Diagnostic criteria, disease risk factors and potential pathogenic mechanisms were all considered. The mechanisms of the diabetogenic effect of modern immunosuppressive drugs were analysed. The principles of pre- and post-transplantation screening for PTDM and optimal management strategies for patients with PTDM are presented. The current controversial issues concerning the various aspects of PTDM are discussed.
About the Authors
Igor Alexandrovich Sklyanik
Endocrinology Research Centre, Moscow
Russian Federation
Competing Interests:
Russian Federation
MD, Resident o the Endocrinology Research Centre
Competing Interests:
Авторы декларируют отсутствие конфликта интересов, связанных с рукописью.
Minara Shamkhalovna Shamkhalova
Endocrinology Research Centre, Moscow
Russian Federation
Competing Interests:
Russian Federation
MD, PhD, Head of Department of Diabetic Nephropathy and Haemodialysis
Competing Interests:
Авторы декларируют отсутствие конфликта интересов, связанных с рукописью.
Marina Vladimirovna Shestakova
Endocrinology Research Centre, Moscow; Sechenov First Moscow State Medical University, Moscow
Russian Federation
Competing Interests: Авторы декларируют отсутствие конфликта интересов, связанных с рукописью.
Russian Federation
MD, PhD, Corresponding member or Russian Academy of Sciences, Director of Diabetes Institute in Endocrinology Research Centre, Head of Diabetology and Endocrinology Department of Pediatric Faculty in Sechenov First Moscow State Medical University
Competing Interests: Авторы декларируют отсутствие конфликта интересов, связанных с рукописью.
References
1. Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002;62(4):1440-1446. doi:10.1046/j.1523-1755.2002.00582.x
2. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. Wait-listed and transplanted renal allograft recipients. American Journal of Transplantation. 2003;3(5):590-598. doi: 10.1034/j.1600-6143.2003.00082.x
3. Cosio FG, Pesavento TE, Osei K, et al. Post-transplant diabetes mellitus: Increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001;59(2):732-737. doi:10.1046/j.1523-1755.2001.059002732.x
4. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75(10 Suppl):SS3-24. doi:10.1097/01.TP.0000069952.49242.3E
5. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation1. Clinical Transplantation. 2005;19(3):291-298. doi: 10.1111/j.1399-0012.2005.00359.x
6. Association AD. Standards of Medical Care in Diabetes—2014. Diabetes care. 2014;37(Supplement 1):S14-S80. doi: 10.2337/dc14-S014
7. Sharif A, Hecking M, de Vries APJ, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2014;14(9):1992-2000. doi: 10.1111/ajt.12850
8. Baid S, Cosimi a B, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001;72(6):1066-1072. doi:10.1097/00007890-200109270-00015
9. Knobler H, Stagnaro-Green A, et al. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol. 1998;26(1):30-33. doi:10.1097/00004836-199801000-00009
10. Ye X, Kuo HT, Sampaio MS, et al. Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. Clinical Transplantation. 2011;25(6):885-891. doi: 10.1111/j.1399-0012.2010.01383.x
11. Miller L. Heart transplantation in patients with diabetes. Circulation. 2006;114(21):2206-2207. doi: 10.1161/circulationaha.106.660902
12. Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Transplantation. 2009;9:S1-S155. doi: 10.1111/j.1600-6143.2009.02834.x
13. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes Mellitus after Kidney Transplantation in the United States. American Journal of Transplantation. 2003;3(2):178-185. doi: 10.1034/j.1600-6143.2003.00010.x
14. Sulanc E, Lane JT, Puumala SE, et al. New-Onset diabetes after kidney transplantation: An Application of 2003 International Guidelines. Transplantation. 2005;80(7):945-952. doi:10.1097/01.TP.0000176482.63122.03
15. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation. 1998;65(4):515-523. doi:10.1097/00007890-199802270-00011
16. Chakkera HA, Hanson RL, Raza SM, et al. Pilot Study: Association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation. Transplantation proceedings. 2009;41(10):4172-4177. doi: 10.1016/j.transproceed.2009.08.063
17. Martı́nez-Castelao A, Hernández MD, Pascual J, et al. Detection and treatment of post kidney transplant hyperglycemia: A Spanish multicenter cross-sectional study. Transplantation Proceedings. 2005;37(9):3813-3816. doi: 10.1016/j.transproceed.2005.10.035
18. Ghisdal L, Van Laecke S, Abramowicz MJ, et al. New-onset diabetes after renal transplantation: risk assessment and management. Diabetes care. 2012;35(1):181-188. doi: 10.2337/dc11-1230
19. Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nature genetics. 2010;42(7):579-589. doi: 10.1038/ng.609
20. Ghisdal L, Baron C, Le Meur Y, et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. Journal of the American Society of Nephrology : JASN. 2009;20(11):2459-2467. doi: 10.1681/ASN.2008121314
21. Hamer RA, Chow CL, Ong ACM, et al. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation. 2007;83(1):36-40. doi:10.1097/01.tp.0000248759.37146.3d
22. Hjelmesæth J, Hartmann A. Insulin resistance in patients with adult polycystic kidney disease. Nephrology Dialysis Transplantation. 1999;14(10):2521-2522. doi: 10.1093/ndt/14.10.2521
23. Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. American Journal of Transplantation. 2006;6(10):2232-2237. doi: 10.1111/j.1600-6143.2006.01457.x
24. Kamar N, Toupance O, Buchler M, et al. evidence that clearance of hepatitis C virus RNA after α-Interferon therapy in dialysis patients is sustained after renal transplantation. Journal of the American Society of Nephrology. 2003;14(8):2092-2098. doi: 10.1097/01.asn.0000079613.81511.3c
25. Hjelmesæth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia. 2004;47(9):1550-1556. doi: 10.1007/s00125-004-1499-z
26. Hjelmesæth J, Müller F, Jenssen T, et al. Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced β-cell damage. Nephrology Dialysis Transplantation. 2005;20(11):2311-2315. doi: 10.1093/ndt/gfi033
27. Pham PCT, Pham PMT, Pham SV, et al. Hypomagnesemia in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology. 2007;2(2):366-373. doi: 10.2215/cjn.02960906
28. Van Laecke S, Van Biesen W, Verbeke F, et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. American Journal of Transplantation. 2009;9(9):2140-2149. doi: 10.1111/j.1600-6143.2009.02752.x
29. Augusto JF, Subra JF, Duveau A, et al. Relation between pretransplant magnesemia and the risk of new onset diabetes after transplantation within the first year of kidney transplantation. Transplantation. 2014;97(11):1155-1160. doi:10.1097/01.TP.0000440950.22133.a1
30. Bonato V, Barni R, Cataldo D, et al. Analysis of Posttransplant Diabetes Mellitus Prevalence in a Population of Kidney Transplant Recipients. Transplantation Proceedings.40(6):1888-1890. doi: 10.1016/j.transproceed.2008.05.045
31. Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation. 2006;82(12):1673-1676. doi:10.1097/01.tp.0000250756.66348.9a
32. Bayer ND, Cochetti PT, Anil Kumar MS, et al. Association of metabolic syndrome with development of new onset diabetes after transplantation. Transplantation. 2010;90(8):861-866. doi: 10.1097/TP.0b013e3181f1543c
33. Israni AK, Snyder JJ, Skeans MA, et al. Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant. Transplant International. 2012;25(7):748-757. doi: 10.1111/j.1432-2277.2012.01488.x
34. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Annals of the Rheumatic Diseases. 2009;68(7):1119-1124. doi: 10.1136/ard.2008.092163
35. Hjelmesæth J, Hartmann A, Kofstad J, et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrology Dialysis Transplantation. 2001;16(4):829-835. doi: 10.1093/ndt/16.4.829
36. Midtvedt K, Hjelmesæth J, Hartmann A, et al. insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. Journal of the American Society of Nephrology. 2004;15(12):3233-3239. doi: 10.1097/01.asn.0000145435.80005.1e
37. Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation. 2011;91(3):334-341. doi:10.1097/TP.0b013e318203c25f
38. Depczynski B, Daly B, Campbell LV, et al. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabetic Medicine. 2000;17(1):15-19. doi: 10.1046/j.1464-5491.2000.00206.x
39. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. American Journal of Transplantation. 2007;7(6):1506-1514. doi: 10.1111/j.1600-6143.2007.01749.x
40. Ким И.Г., Столяревич Е.С., Артюхина Л.Ю., Фролова Н.Ф., Федорова Н.Д., Томилина Н.А. Влияние режима поддерживающей иммуносупрессивной терапии на отдаленные результаты трансплантации почки. // Нефрология и диализ. – 2012. – Т. 14. - №2 – С.41–47. [Kim IG, Stolyarevich ES, Artuhina LYu, et. al. The influence of maintaining immunosuppressive regimen on late results of kidney transplantation. Nephrology and dialysis. 2012;14(1):41-47.]
41. Dong M, Parsaik AK, Eberhardt NL, et al. Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation. Diabetic Medicine. 2012;29(7):e1-e12. doi: 10.1111/j.1464-5491.2012.03617.x
42. Plaumann S, Blume R, Börchers S, et al. Activation of the dual-leucine-zipper-bearing kinase and induction of β-cell apoptosis by the immunosuppressive drug cyclosporin A. Molecular Pharmacology. 2008;73(3):652-659. doi: 10.1124/mol.107.040782
43. Soleimanpour SA, Crutchlow MF, Ferrari AM, et al. Calcineurin signaling regulates human islet β-cell survival. The Journal of biological chemistry. 2010;285(51):40050-40059. doi: 10.1074/jbc.M110.154955
44. Rickels MR, Mueller R, Teff KL, Naji A. β-cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. The Journal of clinical endocrinology and metabolism. 2010;95(3):1238-1246. doi: 10.1210/jc.2009-2289
45. Rostambeigi N, Lanza IR, Dzeja P, et al. Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. Transplantation. 2011;91(6):615-623. doi: 10.1097/TP.0b013e3182094a33
46. Chakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013;95(5):10.1097/TP.1090b1013e31826e31592e. doi: 10.1097/TP.0b013e31826e592e
47. Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. Journal of the American Society of Nephrology : JASN. 2008;19(7):1411-1418. doi: 10.1681/ASN.2007111202
48. Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes, Obesity and Metabolism. 2001;3(6):393-402. doi: 10.1046/j.1463-1326.2001.00150.x
49. Shimodahira M, Fujimoto S, Mukai E, et al. Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism. Journal of Endocrinology. 2010;204(1):37-46. doi: 10.1677/joe-09-0216
50. Inoki K, Ouyang H, Li Y, Guan K-L. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev. 2005;69(1):79-100. doi:10.1128/MMBR.69.1.79-100.2005.
51. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22(2):159-168. doi:10.1016/j.molcel.2006.03.029.
52. Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: An underdiagnosed phenomenon. Transplantation. 2006;82(12):1667-1672. doi:10.1097/01.tp.0000250924.99855.42.
53. Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23(4):739-749. doi:10.1681/ASN.2011080835.
54. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A. 1994;91(11):4854-4858. doi:10.1073/pnas.91.11.4854.
55. Chakkera H a., Weil EJ, Castro J, et al. Hyperglycemia during the immediate period after kidney transplantation. Clin J Am Soc Nephrol. 2009;4(4):853-859. doi:10.2215/CJN.05471008.
56. Inoki K, Ouyang H, Li Y, Guan K-L. Signaling by Target of Rapamycin Proteins in Cell Growth Control. Microbiology and Molecular Biology Reviews. 2005;69(1):79-100. doi: 10.1128/MMBR.69.1.79-100.2005
57. Flechner SM, Glyda M, Cockfield S, et al. The ORION Study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. American Journal of Transplantation. 2011;11(8):1633-1644. doi: 10.1111/j.1600-6143.2011.03573.x
58. Jenssen T, Hartmann A. Prevention and management of transplant-associated diabetes. Expert Opinion on Pharmacotherapy. 2011;12(17):2641-2655. doi: doi:10.1517/14656566.2011.628936
59. Aasebø W, Midtvedt K, Valderhaug TG, et al. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. Nephrology Dialysis Transplantation. 2010;25(4):1289-1293. doi: 10.1093/ndt/gfp617
60. Pilmore HL. Review: Metformin: Potential benefits and use in chronic kidney disease. Nephrology. 2010;15(4):412-418. doi: 10.1111/j.1440-1797.2010.01328.x
61. Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation—a randomized, double-blind, placebo-controlled trial. American Journal of Transplantation. 2014;14(1):115-123. doi: 10.1111/ajt.12518
Supplementary files
Review
For citations:
Sklyanik I.A., Shamkhalova M.Sh., Shestakova M.V. Post-transplantation diabetes mellitus: an overview. Diabetes mellitus. 2015;18(2):20-31. https://doi.org/10.14341/DM2015220-31
Views:
1765
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
